Glucagon-like peptide-1 receptor agonists (GLP-1RAs) appear to reduce both nontraumatic subarachnoid hemorrhage (SAH) and mortality in patients with intracranial aneurysms (IAs) and type 2 diabetes. A retrospective cohort study using the global TriNetX database compared patients with unruptured IAs and type 2 diabetes who received GLP-1Ras with those who did not receive GLP-1RAs. After 1:1 propensity score matching on 95 variables, each cohort included 2,275 patients. The researchers found that GLP‑1RA users had a 34% lower risk of nontraumatic SAH (HR 0.66; 95% CI 0.50–0.87) and a 37% lower risk of all‑cause mortality (HR 0.63; 95% CI 0.52–0.76) over 5 years compared with matched nonusers. A subgroup excluding those with prior aneurysm treatment showed similar reductions in SAH (HR 0.68; 95% CI 0.47–0.98) and mortality (HR 0.64; 95% CI 0.53–0.77). Falsification analysis ruled out confounding by indication and health care access bias. Further study is needed to confirm these findings, the researchers report.